SEC Comment Letter 0000000000-24-010161 to Akebia Therapeutics, Inc. (AKBA) (CIK 0001517022) (AKBA)
Akebia Therapeutics, Inc. (AKBA) (CIK 0001517022)
Date: Sept. 9, 2024 · CIK: 0001517022 · Accession: 0000000000-24-010161
AI Filing Summary & Sentiment
File numbers found in text: 333-281903
Letter
September 9, 2024 John Butler Chief Executive Officer Akebia Therapeutics, Inc. 245 First Street Cambridge, MA 02142 Re:Akebia Therapeutics, Inc. Registration Statement on Form S-3 Filed September 3, 2024 File No. 333-281903 Dear John Butler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Caroline Dotolo
Show Raw Text
September 9, 2024
John Butler
Chief Executive Officer
Akebia Therapeutics, Inc.
245 First Street
Cambridge, MA 02142
Re:Akebia Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 3, 2024
File No. 333-281903
Dear John Butler:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Caroline Dotolo